InsiderTrades.com logo

INM Insider Trading

Insider Ownership Percentage: 0.85%
Insider Buying (Last 12 Months): $1,123,271.10
Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Share Price & Price History

Current Price: $1.66
Price Change: ▲ Price Increase of +0.01 (0.61%)
As of 07/9/2026 04:00 PM ET

This chart shows the closing price history over time for INM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

InMed Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/2/2026Vivo Opportunity, LlcMajor ShareholderBuy1,607$1.55$2,490.85724,395View SEC Filing Icon  
7/1/2026Vivo Opportunity, LlcMajor ShareholderBuy4,344$1.55$6,733.20722,935View SEC Filing Icon  
6/30/2026Vivo Opportunity, LlcMajor ShareholderBuy600$1.54$924.00718,989View SEC Filing Icon  
6/8/2026Vivo Opportunity, LlcMajor ShareholderBuy32,500$1.52$49,400.00718,444View SEC Filing Icon  
6/5/2026Vivo Opportunity, LlcMajor ShareholderBuy55,011$1.57$86,367.27688,926View SEC Filing Icon  
6/4/2026Vivo Opportunity, LlcMajor ShareholderBuy6,743$1.57$10,586.51638,960View SEC Filing Icon  
6/3/2026Vivo Opportunity, LlcMajor ShareholderBuy7,783$1.55$12,063.65632,835View SEC Filing Icon  
6/2/2026Vivo Opportunity, LlcMajor ShareholderBuy22,848$1.52$34,728.96625,766View SEC Filing Icon  
6/1/2026Vivo Opportunity, LlcMajor ShareholderBuy16,336$1.55$25,320.80605,013View SEC Filing Icon  
5/29/2026Vivo Opportunity, LlcMajor ShareholderBuy17,796$1.57$27,939.72590,175View SEC Filing Icon  
5/21/2026Vivo Opportunity, LlcMajor ShareholderBuy34,000$1.69$57,460.00574,011View SEC Filing Icon  
5/20/2026Vivo Opportunity, LlcMajor ShareholderBuy56,210$1.56$87,687.60543,129View SEC Filing Icon  
5/19/2026Adar1 Capital Management, LlcMajor ShareholderBuy468,551$1.54$721,568.54800,000View SEC Filing Icon  
2/21/2024Andrew HullDirectorBuy1,875$7.80$14,625.001,912View SEC Filing Icon  
2/20/2024Eric A. AdamsCEOBuy2,080$7.20$14,976.002,197View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

20.12% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

InMed Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2026Sabby Management LLC201,633$0.21M0.3%-8.3%6.905%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC20,369$45K0.0%N/A0.727%Search for SEC Filing on Google Icon
11/14/2025Sabby Management LLC219,998$0.48M0.6%N/A7.857%Search for SEC Filing on Google Icon
2/14/2025AdvisorShares Investments LLC38,460$0.18M0.0%-94.8%5.342%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC205,968$86K0.0%N/A3.916%Search for SEC Filing on Google Icon
11/14/2022Armistice Capital LLC90,000$0.59M0.0%-90.6%9.605%Search for SEC Filing on Google Icon
5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals

Today's Range

Now: $1.66
Low: $1.60
High: $1.66

50 Day Range

MA: $1.36
Low: $0.62
High: $1.73

52 Week Range

Now: $1.66
Low: $0.58
High: $3.28

Volume

12,919 shs

Average Volume

37,094 shs

Market Capitalization

$5.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?

InMed Pharmaceuticals' top insider investors include:
  1. Adar1 Capital Management, Llc (Major Shareholder)
  2. Vivo Opportunity, Llc (Major Shareholder)
  3. Eric A Adams (CEO)
  4. Andrew Hull (Director)
  5. Bruce Colwill (CFO)
  6. Shane Aaron Johnson (SVP)
Learn More about top insider investors at InMed Pharmaceuticals.

InMed Pharmaceuticals Active Insiders

Eric A Adams
Eric A Adams (Age 62)
CEO
Bruce Colwill
Bruce Colwill (Age 61)
CFO
Shane Aaron Johnson
SVP